	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	335	374	509	558	489	534	721	892	1,049	1,187	1,412	1,682	1,454	1,667	1,723
Cost of Operating Revenue	240	237	348	355	282	339	522	601	667	736	956	1,120	965	1,063	993
Gross Profit	95	137	161	203	208	194	198	292	382	451	456	562	489	603	730
Gross Margin	28.4	36.6	31.6	36.4	42.5	36.4	27.5	32.7	36.5	38.0	32.3	33.4	33.6	36.2	42.4
Total Operating Expenses	318	339	456	486	412	523	732	851	951	1,035	1,315	1,531	1,327	1,522	1,699
Operating Profit	17	34	53	72	77	11	-11	41	98	153	97	151	127	145	25
Operating Margin	5.0	9.1	10.4	12.9	15.7	2.1	-1.5	4.6	9.3	12.8	6.9	9.0	8.8	8.7	1.4
Financing Income/(Expense) - Net	-15	-18	-25	-25	-23	-27	-27	-37	-41	-51	-11	-65	-82	-95	-73
Profit before Taxes	11	24	35	53	50	-6	-31	17	58	105	94	80	59	49	-32
Income Taxes	7	8	6	-2	14	-2	-7	14	28	40	34	41	6	0	0
Profit after Tax	4	15	29	55	36	-11	-30	1	30	51	61	52	-93	-139	28
PAT Margin	1.1	4.0	5.6	9.9	7.3	-2.1	-4.1	0.1	2.9	4.3	4.3	3.1	-6.4	-8.3	1.6
EPS - Basic - ex Extraordinary Items	0.40	1.57	2.98	5.64	3.64	-1.07	-2.64	0.05	2.44	4.03	4.54	3.37	3.85	3.96	-1.45
EPS - Diluted - ex Extraordinary Items	0.40	1.56	2.97	5.62	3.63	-1.07	-2.64	0.05	2.44	3.60	4.45	3.33	3.85	3.96	-1.45
EBIT	17	34	53	72	77	11	-11	41	98	153	97	151	127	145	25
EBITDA	30	48	65	88	94	33	16	70	131	197	153	213	184	209	98
EBITDA Margin	9.0	12.8	12.7	15.8	19.2	6.2	2.2	7.8	12.5	16.6	10.8	12.7	12.6	12.5	5.7

Balance Sheet

Abridged

Understanding Balance Sheet

Camlin Fine Sciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	R 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	207	283	257	299	380	419	666	672	675	795	894	1,088	1,001	1,183	1,236
Long-Term Investments	1	1	1	1	3	9	9	9	9	9	25	25	8	25	49
Property Plant & Equipment - Net	68	77	101	96	151	159	219	263	413	537	740	834	802	654	658
Total Non-Current Assets	79	86	116	131	187	253	351	414	559	687	907	972	951	840	1,087
Total Assets	286	369	373	430	567	673	1,016	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324
Total Current Liabilities	196	263	246	262	360	386	471	460	548	478	595	793	732	846	974
Long Term Debt	33	38	29	28	21	51	110	194	221	282	405	422	350	293	337
Total Non-Current Liabilities	36	41	33	33	25	57	112	196	226	291	440	443	362	302	348
Total Liabilities	233	304	279	295	386	442	583	657	774	768	1,035	1,236	1,094	1,149	1,323
Total Shareholders' Equity	53	65	93	135	181	213	371	371	403	643	748	819	865	902	1,041
Minority Interest	-	-	-	-	-	18	62	59	57	70	17	5	-8	-27	-40
Total Equity	53	65	93	135	181	230	433	430	460	713	765	824	857	875	1,001
Total Liabilities & Equity	286	369	373	430	567	673	1,016	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324

Cash Flow

Abridged

Understanding Cash Flow Statement

Camlin Fine Sciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	R 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	17.97	32.51	42.90	65.91	63.76	5.59	-28.03	18.12	90.26	136.39	115.40	138.48	35.76	37.21	-12.09
Working Capital - Increase/(Decrease)	-63.80	5.83	-38.73	-42.60	-15.14	-39.00	-15.27	-79.88	-40.76	-65.93	6.35	-138.79	31.67	-78.42	36.57
Net CF from Operating Activities	-45.83	38.34	4.17	23.30	48.62	-33.41	-43.30	-61.77	49.50	70.46	121.75	-0.31	67.43	-41.21	24.48
Capital Expenditures - Net	10.82	21.15	33.93	27.70	67.06	30.68	19.02	69.15	134.00	83.81	213.79	143.41	60.02	42.45	57.57
Net CF from Investing Activities	-11.87	-21.15	-33.91	-27.70	-66.95	-84.70	-149.42	-6.10	-92.94	-134.21	-250.82	-125.36	-67.73	-77.02	-55.92
Dividends Paid - Cash - Total	1.84	2.31	2.82	3.36	4.33	4.64	-	6.24	2.80	5.42	0.71	13.85	28.13	-	-
Stock - Issuance/(Retirement) - Net	0.32	0.19	0.36	1.34	2.71	57.60	168.59	0.16	-	75.73	94.84	0.55	0.58	223.13	0.54
Debt - LT & ST - Issuance/(Retirement) - Total	56.61	0.82	22.69	10.11	20.41	65.18	41.95	88.67	45.38	16.58	67.23	124.90	14.36	-81.08	35.39
Net Cash Flow from Financing Activities	54.80	-1.68	18.03	8.89	17.37	117.19	210.55	82.60	42.59	86.90	161.37	111.59	-13.19	142.05	35.93
Free Cash Flow to Equity	-0.04	18.01	-7.07	5.71	1.97	1.09	-20.37	-42.24	-39.11	3.24	-24.80	-18.82	21.77	-164.73	2.30
Free Operating CF net dividend	-62.03	14.81	-34.92	-8.30	-22.79	-68.85	-62.57	-137.36	-87.43	-18.84	-92.75	-158.47	-21.27	-83.66	-33.08
Free Operating CF	-60.19	17.12	-32.11	-4.94	-18.46	-64.21	-62.57	-131.12	-84.64	-13.41	-92.04	-144.61	6.86	-83.66	-33.08

Business Segment Analysis

FY End:

Mar 25

Camlin Fine Sciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Fine Chemicals (100.0%)₹ 42.45 Cr

Revenue / Sales

Fine Chemicals (100.0%)₹ 1,666.53 Cr

Assets

Fine Chemicals (100.0%)₹ 2,023.79 Cr

Operating Income

Fine Chemicals (100.0%)₹ 145.02 Cr

Regional Segment Analysis

FY End:

Mar 25

Camlin Fine Sciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India (83.1%)₹ 1,406.84 CrIndia (16.9%)₹ 285.96 Cr

Historical Segment Analysis

Track how Camlin Fine Sciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Fine Chemicals	134	84	214	144	61	42

Frequently Asked Questions

What is the revenue of Camlin Fine Sciences Ltd.?

The latest trailing twelve month revenue of Camlin Fine Sciences Ltd. is ₹ 1,723.31 Cr, reflecting a 1-year growth of 3.41% and a 3-year CAGR of 0.82%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Camlin Fine Sciences Ltd.?

The latest trailing twelve month net profit (PAT) of Camlin Fine Sciences Ltd. is ₹ 27.63 Cr, with a 3-year earnings CAGR of -34.54%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Camlin Fine Sciences Ltd.?

The trailing twelve month EBITDA of Camlin Fine Sciences Ltd. is approximately ₹ 24.50 Cr (based on an operating margin of 1.42%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Camlin Fine Sciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Camlin Fine Sciences Ltd. is -1.45. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Camlin Fine Sciences Ltd.?

The debt-to-equity ratio of Camlin Fine Sciences Ltd. stands at 0.69. The interest coverage ratio is 0.34x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Camlin Fine Sciences Ltd.?

The estimated book value per share of Camlin Fine Sciences Ltd. is 54.20 (derived from a P/B ratio of 2.38 and market price of ₹ 129.05), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Camlin Fine Sciences Ltd.?

The trailing twelve month operating cash flow of Camlin Fine Sciences Ltd. is ₹ 24.48 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Camlin Fine Sciences Ltd. report consolidated or standalone financials?

Camlin Fine Sciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.